Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

557
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
557
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

443
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
443
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

685
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
685
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

293
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
293

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.

HemaSphere·2026
Same author

What next after the first BITE of the CD19 cherry in ALL?

Blood·2026
Same author

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real-World International Experience.

American journal of hematology·2026
Same author

Historical outcomes for patients with stage IA NLPHL: RGlobal nLPHL One Working Group (GLOW) retrospective analyses.

Blood advances·2026
Same author

Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival.

British journal of haematology·2026
Same author

Patient-reported outcomes in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia receiving standard chemotherapy plus quizartinib or placebo (QuANTUM-First): a global, randomised, placebo-controlled, phase 3 trial.

The Lancet. Haematology·2026
Same journal

HER2-mutated lung squamous cell carcinoma responding to trastuzumab deruxtecan followed by pyrotinib: a Case Report.

Frontiers in pharmacology·2026
Same journal

Awareness, attitudes, and self-reported clinical management of antimicrobial-associated neurocognitive adverse effects among healthcare providers in Saudi Arabia.

Frontiers in pharmacology·2026
Same journal

Low-dose dasatinib in second-line therapy or beyond for the treatment of chronic-phase chronic myeloid leukemia: a real-world cohort study.

Frontiers in pharmacology·2026
Same journal

Natural products reshape osteosarcoma cell fate: promoting cell death.

Frontiers in pharmacology·2026
Same journal

<i>Leonurus japonicus</i> Houtt. extract containing isoquercitrin reduces airway inflammation in mice with allergic asthma.

Frontiers in pharmacology·2026
Same journal

Enhancing diabetes treatment by targeted nucleic acid and drug delivery using cell-penetrating peptides, peptide nucleic acids, and receptor targeting.

Frontiers in pharmacology·2026
See all related articles

Related Experiment Video

Updated: Dec 6, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.1K

Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study.

Pushpendra Goswami1, Esther N Oliva2, Tatyana Ionova3

  • 1School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.

Frontiers in Pharmacology
|October 5, 2020
PubMed
Summary
This summary is machine-generated.

The hematological malignancy (HM)-specific patient-reported outcome measure (HM-PRO) demonstrates strong construct validity, confirming its ability to accurately assess health-related quality of life in patients with blood cancers.

Keywords:
HM-PROclinical practiceclinical researchconstruct validityhematological malignancyquality of lifesymptoms

More Related Videos

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.7K
A Three-dimensional Tissue Culture Model to Study Primary Human Bone Marrow and its Malignancies
08:51

A Three-dimensional Tissue Culture Model to Study Primary Human Bone Marrow and its Malignancies

Published on: March 8, 2014

17.0K

Related Experiment Videos

Last Updated: Dec 6, 2025

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.1K
E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.7K
A Three-dimensional Tissue Culture Model to Study Primary Human Bone Marrow and its Malignancies
08:51

A Three-dimensional Tissue Culture Model to Study Primary Human Bone Marrow and its Malignancies

Published on: March 8, 2014

17.0K

Area of Science:

  • Oncology
  • Psychometrics
  • Health Services Research

Background:

  • Validity is crucial for outcome measures, ensuring they accurately reflect what they intend to assess.
  • The hematological malignancy (HM)-specific patient-reported outcome measure (HM-PRO) is a new instrument for clinical practice and research.
  • This study provides evidence for the construct validity of the HM-PRO, focusing on convergent and divergent validity.

Purpose of the Study:

  • To provide evidence for the construct validity of the HM-PRO.
  • To assess the convergent and divergent validity of the HM-PRO against established hematology instruments.
  • To support the reliable use of the HM-PRO in clinical practice and research.

Main Methods:

  • A prospective cross-sectional design was employed.
  • 905 patients with various hematological malignancies were recruited from UK hospitals and patient organizations.
  • Patients completed the HM-PRO, FACT-G, and EORTC QLQ-C30 questionnaires.

Main Results:

  • The HM-PRO Part A total score showed high correlations with functional scales of EORTC QLQ-C30 (e.g., Physical -0.71, Role -0.72) and FACT-G (e.g., Physical -0.74, Overall -0.74).
  • The HM-PRO Part B total score demonstrated high correlations with symptom scales of EORTC QLQ-C30 (e.g., Fatigue -0.74, Pain -0.59) and individual symptom items (e.g., Dyspnea 0.51).
  • All correlations were statistically significant (p < 0.001).

Conclusions:

  • The study provides strong evidence for the construct validity of the HM-PRO.
  • The HM-PRO accurately measures health-related quality of life issues in hematological malignancy patients.
  • This supports the trustworthy interpretation of HM-PRO scores by clinicians in routine practice.